Skip To Main Content

Articles Articles

Järjestä

Suodattimet

Nollaa
  • Terapia-alue
Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4

Does your patient have an existing autoimmune condition? Check for autoimmune type 1 diabetes!

Does your patient have an existing autoimmune condition? Check for autoimmune type 1 diabetes!

Individuals living with other associated autoimmune diseases like celiac disease or autoimmune thyroid disease, are at an increased risk of developing autoimmune type 1 diabetes (T1D) and should be appropriately screened.1-6

Real-life stories from people living with autoimmune T1D

Real-life stories from people living with autoimmune T1D

The progression of autoimmune type 1 diabetes (T1D) is gradual, often detectable months or even years before symptoms arise.1–3 Through proactive screening, we can identify the condition well in advance.3 Meet our ambassadors living with autoimmune T1D and discover the risk factors to look out for when considering who to screen.

Autoimmune Type 1 Diabetes

Autoimmune Type 1 Diabetes

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.1-4 

The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2

EFLUELDA<sup>®</sup> - korkea-annoksinen influenssarokote

▼EFLUELDA - korkea-annoksinen influenssarokote

Tähän lääkevalmisteeseen kohdistuu lisäseuranta.

Why Choose Toujeo<sup>®</sup> (Insulin Glargine)

Why Choose Toujeo® (Insulin Glargine)

Fabry disease

Fabry disease

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

How to diagnose Fabry

How to diagnose Fabry

Think Fabry, think timely testing first.

Monitoring disease progression

Monitoring disease progression

Think Fabry, think regular profile-based assessments.

Cardiac involvement in Fabry disease

Cardiac involvement in Fabry disease

Cardiovascular disease is the leading cause of death in fabry disease patients.1 Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.2,3

Renal involvement in Fabry disease

Renal involvement in Fabry disease

Think Fabry, think renal involvement that may present early in life and could go undetected.

Family screening

Family screening

Think Fabry, think screening at-risk family members.1